CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS

CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS

Show other versions (1)

<p>The paper gives the comparative results of chemoprevention against prostate cancer (PC) in 189 patients with benign prostate hyperplasia with a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng/ml during 4‑year combined (avodart + omnic) or monotherapy with either drug. Biopsy reveale...

Full description

Bibliographic Details
Main Authors: Yu. I. Kushniruk, V. A. Yarosh, M. D. Dyachuk
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Onkourologiâ
Subjects:
prostate cancer
chemoprevention
benign prostate hyperplasia
combination therapy
monotherapy
avodart
omnic
Online Access:http://oncourology.abvpress.ru/index.php/oncur/article/view/139

Similar Items

Similar Items